Back to Parkinsons Disease
This trial is complete. It is no longer accepting participants. Results may be available on ClinicalTrials.gov.

NCT03781167

NCT03781167
Completed Phase 3 🇦🇺 Australian site

Who may be able to join

Who might be able to join this trial:

  • You have been diagnosed with Parkinson's Disease that responds to a medication called levodopa
  • Your doctor feels your Parkinson's symptoms are not well enough controlled by your current treatment
  • You experience noticeable periods when your medication is working well ("On" time) and periods when it is not working as well ("Off" time)
  • You have at least 2.5 hours per day when your Parkinson's symptoms are not well controlled ("Off" time)

Who may not be able to join:

  • You have problems with memory or thinking that would make it difficult to safely use the drug delivery device, fill in daily diaries, or follow the study instructions
  • The doctor running the trial does not think you would be a suitable candidate for the study medication (ABBV-951) for any reason (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Trial details

Status
Completed
Phase
Phase 3
Sponsor
AbbVie
Registry
clinicaltrials_gov
Start date
29 April 2019
Est. completion
17 August 2022

Where this trial is recruiting

🇦🇺 Australia 🇧🇪 Belgium 🇨🇦 Canada 🇩🇰 Denmark 🇩🇪 Germany 🇮🇹 Italy 🇯🇵 Japan 🇳🇱 Netherlands 🇷🇺 Russia 🇪🇸 Spain 🇸🇪 Sweden 🇬🇧 United Kingdom 🇺🇸 United States

5 site(s) in Australia. Confirm current status and contact details directly with the trial site.

Primary endpoints

Number of Participants With Adverse Events; Number of Participants With Adverse Events of Special Interest; Number of Participants With Numeric Grade Equal to or Higher Than 5 and With Letter Grade Equal to or Higher Than D on the Infusion Site Evaluation Scale; Hematocrit (Hematology): Change From Baseline to End of Study; Hemoglobin (Hematology): Change From Baseline to End of Study; Red Blood Cell (RBC) Count (Hematology): Change From Baseline to End of Study; White Blood Cell (WBC) Count (Hematology): Change From Baseline to End of Study; Neutrophils (Hematology): Change From Baseline to E...

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

View original record on ClinicalTrials.gov